May 2022 - Volume 81 - 5

Recommendation

1. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS

Viewpoint

2. Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors

Heroes and pillars of rheumatology

3. Marking the 50th anniversary of a seminal paper in rheumatology: did Baruj Benacerraf and Hugh McDevitt get it right?

Rheumatoid arthritis

4. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis

Systemic lupus erythematosus

5. Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE

Sjögren’s syndrome

6. Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren’s syndrome

Vasculitis

7. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

Paediatric rheumatology

8. Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA

Osteoarthritis

9. Osteoarthritis endotype discovery via clustering of biochemical marker data

10. Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7

Epidemiology

11. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

12. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

13. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis

14. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases

15. Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study

Letters

16. Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series

17. Management of contemporary early undifferentiated arthritis: data on EULAR’s recommendation on the risk of persistent disease

18. Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies

19. Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern

20. Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series

Electronic pages

21. Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population

22. Response to: ‘Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population’ by Matthijssen et al

23. Comment on: ‘Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population’ by Kishikawa et al

24. Response to: ‘Comment on ‘Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population’ by Kishikawa et al.’ by Kitamura et al

25. Neuroinflammatory events after anti-TNFα therapy

26. Response to: ‘Neuroinflammatory events after anti-TNFα therapy’ by Kaltsonoudis et al

27. Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus

28. Response to: ‘Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus’ by Wu et al

29. Physician’s global assessment is often useful in SLE, but not always: the case of clinical remission

30. Response to: ‘Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission’ by Zen et al

31. Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

32. Response to: ‘Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?’ by Chessa et al

33. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopaenic purpura

34. Response to ‘Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura’ by Xie and Zhang

35. Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a need for a more accurate control group?

36. Response to: ‘Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a need for a more accurate control group?’ by Mertz and Arnaud

37. Associations of regular glucosamine use with all-cause and cause-specific mortality: causality assumptions need to be checked

38. Response to: ‘Associations of regular glucosamine use with all-cause and cause-specific mortality: causality assumptions need to be checked’ by Safiri and Mansournia

39. ‘Finding the right one’

40. Response to: ‘Finding the right one’ by Zanwar

Issue Information

Table of Contents (PDF)

Front Matter (PDF)